兰月娇, 程明涵, 高建*. S期激酶相关蛋白2在纤维化疾病中的作用机制研究进展J. 药学学报, 2021,56(11): 2908-2915. doi: 10.16438/j.0513-4870.2021-0863
引用本文: 兰月娇, 程明涵, 高建*. S期激酶相关蛋白2在纤维化疾病中的作用机制研究进展J. 药学学报, 2021,56(11): 2908-2915. doi: 10.16438/j.0513-4870.2021-0863
LAN Yue-jiao, CHENG Ming-han, GAO Jian*. Research progress on the mechanisms of S-phase kinase-associated protein 2 in fibrotic diseasesJ. Acta Pharmaceutica Sinica, 2021,56(11): 2908-2915. doi: 10.16438/j.0513-4870.2021-0863
Citation: LAN Yue-jiao, CHENG Ming-han, GAO Jian*. Research progress on the mechanisms of S-phase kinase-associated protein 2 in fibrotic diseasesJ. Acta Pharmaceutica Sinica, 2021,56(11): 2908-2915. doi: 10.16438/j.0513-4870.2021-0863

S期激酶相关蛋白2在纤维化疾病中的作用机制研究进展

Research progress on the mechanisms of S-phase kinase-associated protein 2 in fibrotic diseases

  • 摘要: S期激酶相关蛋白2 (Skp2) 是E3泛素连接酶的组成部分之一,其通过将K48与K63连接的泛素链连接到不同的底物上,起到诱导蛋白酶体介导的蛋白水解或调节标记底物发挥促进细胞增殖与迁移、抑制细胞凋亡与衰老等作用。Skp2是多种纤维化疾病潜在的药物作用靶标,在多种纤维化疾病中呈现高表达,且调控疾病的发生发展。本文在介绍Skp2的归属、结构、下游靶标以及细胞机制调控的基础上,重点阐述Skp2在多种纤维化疾病如肝纤维化、特发性肺纤维化、肾纤维化、角膜纤维化和心脏纤维化中的研究进展,以期为临床开发靶向Skp2的纤维化治疗药物提供新的研究思路。

     

    Abstract: S-phase kinase-associated protein 2 (Skp2) is one of the components of E3 ubiquitin ligase, which can induce proteasome-mediated proteolysis or regulate labeled substrates to promote cell proliferation and migration and inhibit cell apoptosis and senescence by connecting the ubiquitin chains of K48 and K63 to different substrates. Skp2 is also a potential drug target in a variety of fibrotic diseases, is highly expressed in a variety of fibrotic diseases, and regulates the occurrence and progression of these diseases. This paper reviews Skp2's structure, downstream targets, and cellular regulation and then focuses on research progress on Skp2 in various fibrotic diseases, such as liver fibrosis, idiopathic pulmonary fibrosis, renal fibrosis, corneal fibrosis, and cardiac fibrosis, which may help provide a new research approaches for clinical development of Skp2-targeted antifibrotic drugs.

     

/

返回文章
返回